42 U.S.C. § 285d–5 — Arthritis and musculoskeletal diseases demonstration projects
submitted 82 years ago by Pub. L. 99-158 to r/title-42-THE-PUBLIC-HEALTH-AND-WELFARE · 397 words · no verdicts yet
The Institute's Director may fund public and private groups to run arthritis demonstration projects. These projects test better ways to screen, detect, refer, and treat arthritis and musculoskeletal diseases. The Director must also standardize how patient data is recorded and shared.
(a) Grants for establishment and support: The Director* of the Institute may give grants to public and private nonprofit groups to set up projects that develop and demonstrate methods for screening, detecting, and referring people for arthritis and musculoskeletal disease treatment*, and for sharing information on these methods with health professionals. These projects must be coordinated with federal, state*, local, and regional health agencies, with centers funded under section 285d–6, and with the data system described in subsection (c).
(b) Programs included: Funded projects must include:
(1) programs developing and demonstrating new, better ways to screen, detect early, refer, and diagnose people at risk;
(2) programs developing and demonstrating better ways to refer patients from local hospitals and doctors to specialized centers for early diagnosis and treatment;
(3) programs developing better, standardized ways to record and manage patient data;
(4) programs developing better ways to share knowledge about the methods in paragraphs (1) through (3) with health professionals;
(5) programs developing better ways to share information with the general public — (A) about the importance of early detection, prompt treatment, and following the right treatment plan, and (B) to discourage unapproved, ineffective diagnosis, prevention, treatment, and control methods, and unapproved, ineffective drugs and devices; and
(6) projects investigating the epidemiology of arthritis and musculoskeletal diseases in all its forms, including social, environmental, behavioral, nutritional, and genetic factors.
(c) Standardization of patient data and recordkeeping: The Director must standardize how patient data is collected, stored, analyzed, retrieved, and shared, working with the projects funded here, the centers funded under section 285d–6, and others working on arthritis and musculoskeletal disease programs.
The Director* of the Institute may make grants to public and private nonprofit entities to establish and support projects for the development and demonstration of methods for screening, detection, and referral for treatment* of arthritis and musculoskeletal diseases and for the dissemination of information on such methods to the health and allied health professions. Activities under such projects shall be coordinated with Federal, State*, local, and regional health agencies, centers assisted under section 285d–6 of this title, and the data system established under subsection (c).
Projects supported under this section shall include—
programs which emphasize the development and demonstration of new and improved methods of screening and early detection, referral for treatment, and diagnosis of individuals with a risk of developing arthritis and musculoskeletal diseases;
programs which emphasize the development and demonstration of new and improved methods for patient referral from local hospitals and physicians to appropriate centers for early diagnosis and treatment;
programs which emphasize the development and demonstration of new and improved means of standardizing patient data and recordkeeping;
programs which emphasize the development and demonstration of new and improved methods of dissemination of knowledge about the programs, methods, and means referred to in paragraphs (1), (2), and (3) of this subsection to health and allied health professionals;
programs which emphasize the development and demonstration of new and improved methods for the dissemination to the general public of information—
on the importance of early detection of arthritis and musculoskeletal diseases, of seeking prompt treatment, and of following an appropriate regimen; and
to discourage the promotion and use of unapproved and ineffective diagnostic, preventive treatment, and control methods for arthritis and unapproved and ineffective drugs and devices for arthritis and musculoskeletal diseases; and
projects for investigation into the epidemiology of all forms and aspects of arthritis and musculoskeletal diseases, including investigations into the social, environmental, behavioral, nutritional, and genetic determinants and influences involved in the epidemiology of arthritis and musculoskeletal diseases.
The Director shall provide for the standardization of patient data and recordkeeping for the collection, storage, analysis, retrieval, and dissemination of such data in cooperation with projects assisted under this section, centers assisted under section 285d–6 of this title, and other persons engaged in arthritis and musculoskeletal disease programs.
Source credit: (July 1, 1944, ch. 373, title IV, § 440, as added Pub. L. 99–158, § 2, Nov. 20, 1985, 99 Stat. 850.)
- 1944Enacted · Pub. L. 99-158 · 99 Stat. 850
A history note hasn’t been published yet. The record shows enactment by Pub. L. 99-158 on 1944-07-01.
all 0 arguments · sorted by: best
no arguments yet — make the first case